A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone.
The findings were part of the results of a Phase III clinical trial presented today at the Society for Neuro-Oncology’s 19th Annual Meeting in Miami by the study’s primary author Jan Buckner, M.D., deputy director, practice, at Mayo Clinic Cancer Center. “On average, patients who received PCV lived 5.5 years longer than those who received radiation alone,” says Dr. Buckner.
This article originally appeared on Cancer Therapy Advisor
READ FULL ARTICLE From Medical Express